Pheno Therapeutics Announces UCB Worldwide License for New Neurodegenerative Diseases Program | More news

Pheno Therapeutics Announces Worldwide License from UCB for New Neurodegenerative Diseases Program

Preclinical program with disease-modifying therapeutic potential

EDINBURGH, UK I 11 January 2023 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapies that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, today announced it has entered into an exclusive worldwide licensing agreement with UCB. The agreement gives Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical program of new small molecules designed to promote remyelination.

“Pheno Therapeutics has utilized its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to accelerate a promising drug target into clinical development,” said Fraser Murray, PhD., Chief Executive Officer of Pheno Therapeutics. “Together with our experience developing human neurological drugs, Pheno Therapeutics offers significant opportunities to accelerate this program toward proof-of-concept clinical trials and potentially deliver transformative medicines for the treatment of demyelinating diseases.”

“Licensing deals like this are a demonstration of the value that UCB scientists and our partners are creating through strong research productivity, and we are confident that Pheno Therapeutics, with its expertise in phenotypic screening, stem cell technology and biology, will develop this preclinical program to its full potential,” said Dhaval Patel, executive vice president and chief scientific officer at UCB.

Pheno Therapeutics will make a one-time upfront payment and will be responsible for global development, manufacturing and commercialization. UCB will receive tiered milestones and royalties on net sales. Further financial details of the deal were not disclosed.

Program information:

The preclinical program is a novel small molecule program designed to selectively modulate the activity of an undisclosed target that is preferentially expressed on human oligodendrocytes and is known to play a critical role in the biological pathway and process of myelination. The therapeutic program was developed by Pheno Therapeutics under an exclusive worldwide license from UCB.

About Pheno Therapeutics:

Pheno Therapeutics is a discovery and development-focused biotechnology company developing small molecule therapies that enhance human oligodendrocytes function and their natural ability to promote remyelination for the treatment of neurological diseases with high unmet medical needs such as multiple sclerosis (SM). MS is a devastating chronic disease with significant individual and social impact that often manifests in young adults and is associated with a wide range of neurological symptoms that can progress to total physical and cognitive disability. Pheno Therapeutics is looking to promote remyelination and reverse the critical demyelination aspect of MS. MS demyelination occurs when the immune system attacks and damages the myelin sheaths that insulate and nourish axons and nerve fibers in the central nervous system, leading to multifocal demyelination, axonal damage, and neurodegeneration. For more information about Pheno Therapeutics, visit

SOURCE: Pheno Therapeutics

Add a Comment

Your email address will not be published. Required fields are marked *